Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

ClinicalTrials.gov ID: NCT02581631

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02581631. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination With Brentuximab Vedotin in Subjects With Relapsed Refractory Non Hodgkin Lymphomas With CD30 Expression (CheckMate 436: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 436)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine whether Nivolumab, in combination with brentuximab vedotin, is safe and effective in patients with certain subtypes of non-Hodgkin's lymphomas with CD30 expression that have not responded to treatment or have come back. The subtypes we are studying are Diffuse Large B-Cell Lymphoma (DLBCL), Peripheral T-Cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Primary Mediastinal Large B-Cell Lymphoma (PMBL) and Mediastinal Gray Zone Lymphoma (MGZL).

Study identification

NCT ID
NCT02581631
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
145 participants

Conditions and interventions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range
15 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 11, 2016 (Actual)
Primary completion
Jan 16, 2020 (Actual)
Completion
Feb 7, 2022 (Actual)
Last update posted
Mar 7, 2023

2016 – 2022

United States locations

U.S. sites
16
U.S. states
13
U.S. cities
15
Facility City State ZIP Site status
Local Institution - 0017 Birmingham Alabama 35294-3300 —
University Of Miami Sylvester Comprehensive Cancer Center Miami Florida 33136 —
Local Institution - 0012 Tampa Florida 33612 —
Winship Cancer Institute. Atlanta Georgia 30322 —
University Of Chicago Chicago Illinois 60637 —
Mayo Clinic Rochester Minnesota 55905 —
Washington University School Of Medicine St Louis Missouri 63110 —
Local Institution - 0003 New York New York 10021 —
Local Institution - 0010 New York New York 10029 —
University Of Rochester Rochester New York 14642 —
Levine Cancer Institute Charlotte North Carolina 28204 —
The Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 —
Stephenson Cancer Center Oklahoma City Oklahoma 73104 —
Providence Portland Medical Center Portland Oregon 97213 —
Bon Secours-St Francis Hosp Greenville South Carolina 29607 —
University of Washington - Seattle Cancer Care Alliance Seattle Washington 98109-1023 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02581631, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 7, 2023 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.